Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zarate

Showing results (521-530 of 606) with videos related to

Pageof 61
Sort By:
Neurotoxicology and Teratology|May 4, 2021
A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801Patrick J Morris, Richard D Burke, Alok K Sharma, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 4, 2011
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew, Meena Vythilingam, James W Murrough, et al.
Journal of Clinical Psychopharmacology|December 1, 2016
Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS StudyRodrigo Machado-Vieira, Marcus V Zanetti, Maria C Otaduy, et al.
Transplantation Proceedings|April 1, 2020
Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case ReportJ Bahena Méndez, L R López Y López, M A Sebastián Díaz, et al.
Molecular Psychiatry|June 29, 2022
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive searchJordi Bonaventura, Juan L Gomez, Meghan L Carlton, et al.
Neuroscience Letters|August 23, 2015
Regulation of leukocyte tricarboxylic acid cycle in drug-naïve Bipolar DisorderRafael T de Sousa, Emilio L Streck, Orestes V Forlenza, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 3, 2015
Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorderRodrigo Machado-Vieira, Marcus V Zanetti, Antonio L Teixeira, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 2, 2004
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen, K N Roy Chengappa, Trisha Suppes, et al.
Epilepsia|June 26, 2025
Stereoelectroencephalography-guided radiofrequency thermocoagulation for drug-resistant epilepsy: A meta-analysisPavel S Pichardo-Rojas, Diego Pichardo-Rojas, Carlos A Zarate-Duran, et al.
Journal of Affective Disorders|February 15, 2020
Development of the Ketamine Side Effect Tool (KSET)Brooke Short, Vanessa Dong, Verònica Gálvez, et al.
Pageof 61

Showing results (521-530 of 606) with videos related to

Sort By:
Pageof 61
Neurotoxicology and Teratology|May 4, 2021
A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801Patrick J Morris, Richard D Burke, Alok K Sharma, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 4, 2011
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew, Meena Vythilingam, James W Murrough, et al.
Journal of Clinical Psychopharmacology|December 1, 2016
Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder: A 3-T 1H-MRS StudyRodrigo Machado-Vieira, Marcus V Zanetti, Maria C Otaduy, et al.
Transplantation Proceedings|April 1, 2020
Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case ReportJ Bahena Méndez, L R López Y López, M A Sebastián Díaz, et al.
Molecular Psychiatry|June 29, 2022
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive searchJordi Bonaventura, Juan L Gomez, Meghan L Carlton, et al.
Neuroscience Letters|August 23, 2015
Regulation of leukocyte tricarboxylic acid cycle in drug-naïve Bipolar DisorderRafael T de Sousa, Emilio L Streck, Orestes V Forlenza, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 3, 2015
Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorderRodrigo Machado-Vieira, Marcus V Zanetti, Antonio L Teixeira, et al.
The British Journal of Psychiatry : the Journal of Mental Science|April 2, 2004
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen, K N Roy Chengappa, Trisha Suppes, et al.
Epilepsia|June 26, 2025
Stereoelectroencephalography-guided radiofrequency thermocoagulation for drug-resistant epilepsy: A meta-analysisPavel S Pichardo-Rojas, Diego Pichardo-Rojas, Carlos A Zarate-Duran, et al.
Journal of Affective Disorders|February 15, 2020
Development of the Ketamine Side Effect Tool (KSET)Brooke Short, Vanessa Dong, Verònica Gálvez, et al.
Pageof 61